Peptonic and Orion bring a new hormone-free treatment for vaginal atrophy to Scandinavian markets
Peptonic chose Orion as the CMO for Vagivital, a hormone-free self-care product for menopausal women. Recently the partnership expanded, as Orion plans to launch and distribute the product in Finland under its own brand name.
40 to 60 % of menopausal and post-menopausal women suffer from vaginal dryness and atrophy. The standard treatment is usually estrogen-based, but hormonal treatments can have a range of unpleasant side effects.
Together with contract manufacturing organization Orion, Peptonic Medical is bringing a new product for the hormone-free treatment of vaginal atrophy to the market.
“Compared to other non-hormonal treatments, VagiVital and its effective symptom relief have been extensively studied in a randomized, double-blind and placebo controlled clinical trial,” says Johan Inborr, CEO of Peptonic Medical. “We have already launched the product through our webshop in Sweden and plan to bring it out to Swedish pharmacies soon.”
GROWING PARTNERSHIP WITH ORION
Peptonic chose Orion as the contract manufacturing partner for VagiVital because of Orion’s extensive experience in producing gels and semisolids. The product is manufactured at Orion’s Turku plant.
“Orion convinced us that they had the right knowhow, equipment and skilled people to be able to produce exactly the kind of challenging formulation that VagiVital is. In addition, their price range was right, and we were able to build the right kind of rapport from the start”, says Inborr. “In all respects, they seemed like a good team to partner with.”
ANOTHER PLUS WAS ORION'S GMP COMPLIANT OPERATIONS
“Even though VagiVital is not a pharmaceutical product, the high quality standards are an advantage. We also have another, oxytocin-based product for the treatment of vaginal atrophy in our pipeline. So, if we decide to move forward with that, it’s great that our CMO partner also has high-level know-how in manufacturing hormonal products.”
Recently, the partnership between the two companies expanded to include a distribution agreement, as Orion plans to launch the VagiVital product in Finland under its own brand name.
“We are very excited about this addition to our partnership. It is of course a great asset that our CMO partner is a fully-fledged pharma company with its own marketing and sales force and a strong position in the Finnish market,” Inborr says. “We are happy to be able to join forces and bring a strong new product to market together.”
Johan Inborr, CEO of Peptonic Medical